ArrowMark Colorado Holdings’s Structure Therapeutics GPCR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.07M	Sell	188,195 -83,018	-31%	-$5.68M	0.24%	126
2025 Q4	$18.9M	Sell	271,213 -51,953	-16%	-$2.12M	0.42%	72
2025 Q3	$9.05M	Buy	323,166 +24,229	+8%	+$483K	0.17%	144
2025 Q2	$6.2M	Buy	298,937 +53,751	+22%	+$1.18M	0.11%	177
2025 Q1	$4.24M	Buy	245,186 +12,277	+5%	+$301K	0.07%	184
2024 Q4	$6.32M	Sell	232,909 -8,183	-3%	-$290K	0.08%	174
2024 Q3	$10.6M	Sell	241,092 -1,808	-0.7%	-$69.9K	0.14%	132
2024 Q2	$9.54M	Sell	242,900 -12,349	-5%	-$507K	0.11%	143
2024 Q1	$10.9M	Sell	255,249 -23,483	-8%	-$990K	0.12%	136
2023 Q4	$11.4M	Buy	278,732 +228,732	+457%	+$13.1M	0.13%	134
2023 Q3	$2.52M	Hold	50,000	–	–	0.03%	224
2023 Q2	$2.08M	Hold	50,000	–	–	0.02%	231
2023 Q1	$1.19M	Buy	+50,000	New	+$1.17M	0.01%	247

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ArrowMark Colorado Holdings's GPCR Position: Q1 2026 in Review

ArrowMark Colorado Holdings reduced its Structure Therapeutics (GPCR) stake by 31% in Q1 2026, selling an estimated $5.68M and leaving 188,195 shares worth $9.07M. The position accounts for 0.24% of the portfolio, ranked #126.

ArrowMark Colorado Holdings first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $18.9M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

ArrowMark Colorado Holdings held 188,195 shares of Structure Therapeutics worth $9.07M as of Q1 2026.
ArrowMark Colorado Holdings sold 83,018 Structure Therapeutics shares in Q1 2026, an estimated $5.68M.
Structure Therapeutics made up 0.24% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #126 holding.
ArrowMark Colorado Holdings first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
ArrowMark Colorado Holdings's Structure Therapeutics position peaked at $18.9M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.